Resources

Featured

Advance procurement: A pragmatic approach to incentivize the development of priority paediatric ARV formulations
December 2018

The many challenges of developing drugs appropriately formulated for children are compounded by a series of market factors that make these efforts costly and complex, discouraging drug manufacturers – especially generic drug manufacturers – from prioritizing investments in new paediatric treatment options. This brief explores the concept of advance procurement as a method for reducing uncertainty within the paediatric ART market and spurring investment in adapted child-friendly drug formulations.

Read more

General

Paediatric HIV

www.gap-f.org
Global Accelerator for Paediatric Formulations (GAP-f) website

CTA/ILF/CIPHER Thematic Roundtable on Paediatric ARVs: Fast tracking development of priority formulations (AIDS 2016)
July 2016

ILF Thematic Roundtable on HIV Diagnostics: Addressing challenges of early infant diagnosis and point-of-care diagnostics (AIDS 2016)
July 2016

ILF/CIPHER Thematic Roundtable on Paediatric ARVs: Stimulating development of the most needed formulations
March 2016

ILF/CIPHER Thematic Roundtable on Paediatric HIV Diagnostics: Early infant diagnosis and beyond (IAS 2015)
July 2015

ILF/CIPHER Thematic Roundtable on Paediatric ARVs: Aligning, coordinating and accelerating actions to provide better ARVs for children
March 2015

IAS-ILF/CIPHER Thematic Roundtable on Paediatric HIV - Removing barriers and seizing opportunities in paediatric HIV (AIDS 2014)
July 2014

Industry Roundtable on Paediatric ARVs - Paediatric antiretrovirals: The barriers to and solutions for improved access to optimal drugs in resource-limited settings
November 2013

Beyond Option B+ (IAS 2013)
July 2013

Catching children before they fall: Addressing the urgent drug development needs of children living with HIV (AIDS 2012)
July 2012

Prevention of vertical transmission and beyond: How to identify, enrol and retain children in treatment programmes in resource-limited settings
July 2012

Pharmacology of ARVs: How HIV-1 infection differs in children and women (CROI 2012)
March 2012

Challenges in the Procurement and Development of Paediatric Antiretroviral Formulations (IAS 2011)
July 2011

Operational and Implementation Challenges in Scaling Up PMTCT Programmes in Resource-Limited Settings (IAS 2011)
July 2011

Environmental Scan: Mapping HIV research priorities for Women and children
July 2010

Consensus Statement – Asking the Right Questions: Advancing an HIV Research Agenda for Women and Children
March 2010

Building Consensus on Clinical and Operations Research Priorities for Women and Children at the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2009)

Final Report: Mapping and Building Consensus on HIV Research Priorities for Women and Children
December 2009

Webcast of consultation meeting

Mapping the Gaps in Clinical Research in Resource-limited Settings: Focus on Paediatric Treatment (CROI 2009)

Environmental Scan: Mapping HIV research priorities for Women and children
July 2010

Consensus Statement – Asking the Right Questions: Advancing an HIV Research Agenda for Women and Children
March 2010

Operations Research on the prevention of mother-to-child transmission of HIV and pediatric HIV care, support & treatment
September 2009

 

Toolkit for research and development of paediatric antiretroviral drugs and formulations
Research toolkit for paediatric HIV drug development developed by the WHO convened Paediatric ARV Working Group (PAWG) in collaboration with Unitaid, IMPAACT and PENTAid – and with support from a number of partners, including the ILF.

Access the toolkit here | Access an online version with slide sets here

The Global Accelerator for Paediatric Formulations (GAP-f): Accelerating the development and uptake of the most needed drug formulations for children
Presented at the 11th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology
Granada, Spain | March 2018

The Global Accelerator for Paediatric Formulations (GAP-f): Ensuring children have accelerated access to optimal drug formulations
Presented at the 4th International HIV/Viral Hepatitis Co-Infection Meeting
Paris, France | July 2017

Regulatory Affairs